CD44 and cancer: In combination with existing reports [24] and GBP1-regulated AS events, a regulatory pathway was finally obtained, that is, GBP1 regulated CD44 protein expression through A3SS alternative splicing after binding to HNRNPK, and finally played a role in promoting cancer (Fig. 16).